Premium
Peripheral inflammatory biomarkers in Alzheimer's disease and mild cognitive impairment: a systematic review and meta‐analysis
Author(s) -
Su Cen,
Zhao Kangren,
Xia Haiping,
Xu Yaoming
Publication year - 2019
Publication title -
psychogeriatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.647
H-Index - 32
eISSN - 1479-8301
pISSN - 1346-3500
DOI - 10.1111/psyg.12403
Subject(s) - biomarker , medicine , inflammation , disease , meta analysis , peripheral , chemokine , cognitive impairment , interleukin 6 , immunology , interleukin , pathogenesis , alzheimer's disease , cytokine , biology , biochemistry
Background In the past few decades, it has been demonstrated with animal models and clinical studies that a chronic inflammatory process significantly contributes to Alzheimer's disease (AD) pathogenesis. Methods We systematically searched on PubMed and Web of Science for studies associated with peripheral inflammatory biomarkers in AD and mild cognitive impairment (MCI) before July 2018. Meta‐analysis was conducted to summarise results of studies relative to peripheral cytokines and chemokines in AD and MCI. Results Mean (± SD) concentrations of peripheral inflammatory biomarkers for AD, MCI and healthy controls were extracted from these studies. Our meta‐analysis revealed consistently elevated concentrations of inflammatory biomarkers such as C‐reactive protein, interleukin‐1β (IL‐1β), IL‐2, IL‐6, IL‐12, IL‐18, monocyte chemotactic protein‐1 (MCP‐1), MCP‐3, IL‐8 and interferon‐γ‐inducible protein 10 in AD patients, whereas no consistent results were obtained for elevated concentrations of cytokines or chemokines except MCP‐1 in MCI patients. Conclusions In conclusion, these results provided evidence to support that systematic inflammation might be a biomarker for AD diagnosis, whereas it might be a later event during AD disease progression.